We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-5.51%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$285M
AUM Growth
-$94.6M
Cap. Flow
-$78.6M
Cap. Flow %
-27.58%
Top 10 Hldgs %
56.44%
Holding
82
New
19
Increased
11
Reduced
16
Closed
32

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$17M
2
QGEN icon
Qiagen
QGEN
+$15.8M
3
ICLR icon
Icon
ICLR
+$11.1M
4
ZTS icon
Zoetis
ZTS
+$7.11M
5
BAX icon
Baxter International
BAX
+$6.52M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$15.9M
2
OFIX icon
Orthofix Medical
OFIX
+$14.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$14.2M
4
CNC icon
Centene
CNC
+$12.5M
5
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 70.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$16.9B
$2.73M 0.96%
+27,992
New +$2.58M
GBT
27
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.59M 0.91%
81,007
+37,757
+87% +$1.11M
THC icon
28
Tenet Healthcare
THC
$20.1B
$2.49M 0.87%
47,442
-83,934
-64% -$5.84M
INCY icon
29
Incyte
INCY
$24.1B
$2.37M 0.83%
+31,211
New +$2.37M
XBI icon
30
State Street SPDR S&P Biotech ETF
XBI
$9.56B
$2.33M 0.82%
31,349
-15,091
-32% -$1.13M
BMRN icon
31
BioMarin Pharmaceuticals
BMRN
$11.6B
$2.15M 0.76%
+25,975
New +$2.07M
DXCM icon
32
DexCom
DXCM
$32.7B
$1.94M 0.68%
+26,046
New +$2.38M
STRO icon
33
Sutro Biopharma
STRO
$403M
$1.86M 0.65%
35,747
+6,096
+21% +$341K
FATE icon
34
Fate Therapeutics
FATE
$291M
$1.77M 0.62%
71,640
+11,908
+20% +$329K
RCUS icon
35
Arcus Biosciences
RCUS
$3.46B
$1.64M 0.58%
64,756
+26,106
+68% +$639K
COR icon
36
Cencora
COR
$60.5B
$1.63M 0.57%
+11,515
New +$1.76M
MMSI icon
37
Merit Medical Systems
MMSI
$5.11B
$1.1M 0.39%
+20,223
New +$1.23M
ACHC icon
38
Acadia Healthcare
ACHC
$2.82B
$1.09M 0.38%
+16,189
New +$1.13M
ZBH icon
39
Zimmer Biomet
ZBH
$18.6B
$1.04M 0.37%
+9,949
New +$1.18M
ALBO
40
DELISTED
Albireo Pharma Inc
ALBO
$751K 0.26%
37,835
-82,999
-69% -$2.19M
HZNP
41
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$674K 0.24%
+8,454
New +$801K
MRVI icon
42
Maravai LifeSciences
MRVI
$948M
$654K 0.23%
+23,015
New +$729K
AXSM icon
43
Axsome Therapeutics
AXSM
$10.7B
$584K 0.2%
15,246
-85,053
-85% -$2.69M
ADCT icon
44
ADC Therapeutics
ADCT
$131M
$469K 0.16%
+58,967
New +$558K
CYTK icon
45
Cytokinetics
CYTK
$10.2B
$453K 0.16%
+11,538
New +$465K
BDSX icon
46
Biodesix
BDSX
$232M
$214K 0.08%
6,538
– –
PRAX icon
47
Praxis Precision Medicines
PRAX
$8.45B
$194K 0.07%
5,273
-24
-0.5% -$2.56K
IMUX icon
48
Immunic
IMUX
$191M
$106K 0.04%
3,059
-9,998
-77% -$641K
AFMD
49
DELISTED
Affimed
AFMD
– –
-35,449
Closed -$1.55M
AHCO icon
50
AdaptHealth
AHCO
$1.51B
– –
-248,314
Closed -$3.98M
1
2
3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Endurant Capital Management held 82 positions worth $285M, down 25% from $380M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Endurant Capital Management withdrew a net $78.6M in Q2 2022, closing 32 positions and reducing 16 holdings. Its most notable exit was AstraZeneca, an estimated $15.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 70% a quarter earlier.

Against the trend, Endurant Capital Management opened a new position in Boston Scientific worth $15.6M.

  • Endurant Capital Management's largest Q2 2022 buy was Boston Scientific: 418,165 shares worth $15.6M.
  • Endurant Capital Management added most to Qiagen in Q2 2022, an estimated $15.8M increase.
  • Endurant Capital Management's biggest Q2 2022 reduction was Centene, cutting an estimated $12.5M.
  • Endurant Capital Management fully exited AstraZeneca in Q2 2022, selling an estimated $15.9M.
  • Endurant Capital Management's ten largest holdings make up 56% of its $285M portfolio in Q2 2022.
  • Endurant Capital Management opened 19 new positions and closed 32 in Q2 2022.
  • Endurant Capital Management's portfolio value fell 25% quarter-over-quarter to $285M.

Based on Endurant Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.